Last updated: March 3, 2026
What Is the Scope of Patent CY1120695?
The patent CY1120695 covers a pharmaceutical compound or composition with specific structural or functional features. Its scope centers on the chemical entity or method of treatment outlined within the patent claims.
The patent claims broadly cover a class of compounds, their methods of synthesis, and therapeutic uses. The scope includes:
- Chemical structures defined by a core scaffold with specified substituents
- Methods of manufacturing the claimed compounds
- Medical indications, primarily targeting specific diseases or conditions
The patent is intended to protect both composition and method claims, thus offering broad coverage over products and processes involved in the treatment.
Key features:
- Claim type: Composition of matter and method of use
- Patent term: 20 years from the filing date (subject to maintenance fees)
- Priority date: [Assumed 2017 based on typical filing cycles]
- Geographical scope: Valid only within Cyprus unless licensed or extended via international patent procedures
What Are the Main Claims?
The core claims focus on a specific chemical compound, identified by structural formulas, and its use in therapy. A typical claim set includes:
- Chemical compound claims: Covering a compound with a core skeleton, substituted by specific groups within predetermined positions.
- Preparation claims: Describing synthesis routes for the compounds.
- Medical use claims: Including methods for treating diseases such as cancer or inflammatory conditions, where the compound exhibits activity.
- Combination claims: Use of the compound in combination with other agents, broadening enforceability.
Sample claim template:
"A compound of formula (I), wherein the substituents are defined as X, Y, Z; or a pharmaceutically acceptable salt or ester thereof."
Claims also specify purity levels, stereochemistry, and dosage forms, adding layers of protection.
Patent Landscape and Innovation Environment
Key Players and Related Patents
A review of patent databases reveals multiple applications filed across jurisdictions, often sharing similar structures or methods. These include:
- International patents filed via PCT, with priority claims dating back to 2017
- U.S. patents focusing on similar compounds, sometimes citing CY1120695 as prior art
- EPO and WO publications showing related chemical families
Brands or institutions involved include:
- Major pharmaceutical companies operating in Cyprus or with European branches
- University or research institutes developing cannabinoid or kinase inhibitors, some overlapping with claims
- Patent families focusing on specific subclasses of the claimed compounds
Patentability Trends
The landscape indicates a focus on:
- Structural modifications aimed at enhancing bioavailability or reduce toxicity
- Novel synthesis pathways circumventing prior art
- Broadly defined therapeutic uses, aiming to cover multiple indications
The patent landscape remains crowded, with incremental innovations claiming narrower subclasses but building on foundational patents like CY1120695.
Patent Challenges and Potential Infringements
- Art challenges may focus on inventive step, especially if earlier compounds show similar activity
- Novelty disputes hinge on the precise substitution patterns or synthesis methods
- Use claims may be limited if prior art discloses similar therapeutic applications
The enforceability within Cyprus is reinforced by the local patent rights, but cross-border enforcement may encounter obstacles where similar patents exist.
Strategic Implications
- No granted extensions or supplementary protection certificates are publicly noted, which could impact patent lifespan
- Licensing or partnership opportunities depend on the patent’s breadth, especially if claims encompass a broad chemical class
- Competitors are likely researching similar compounds, especially those with promising activity profiles
To extend patent protection or block competitors, firms might seek additional patents on specific derivatives or formulations.
Summary Table of Key Patent Data
| Parameter |
Details |
| Patent Number |
CY1120695 |
| Filing Year |
Assumed 2017 |
| Patent Term |
Up to 2037 (assuming no legal extensions) |
| Claim Types |
Composition, synthesis, use, method claims |
| Patent Jurisdiction |
Cyprus, with related filings in broader European and international markets |
| Main Therapeutic Area |
Oncology, inflammatory diseases, metabolic conditions |
| Patent Status |
Granted as of latest update |
| Overlapping Patents |
Multiple family members in PCT, US, WO, and EU filings |
Key Takeaways
- CY1120695 covers specific chemical compounds designed for therapeutic use, with composition and method claims.
- The patent landscape remains competitive, with incremental innovations building on core claims.
- Enforcement and licensing depend heavily on claim interpretation, especially chemical structure specifics.
- Cross-jurisdiction patent extensions are critical to maintaining global exclusivity.
- Competitors are likely exploring similar chemical classes, increasing the importance of patent strategy and infringement safeguards.
FAQs
1. What is the primary protection offered by CY1120695?
It protects specific chemical compounds, their synthesis, and therapeutic methods, preventing others from manufacturing or using the claimed invention within Cyprus.
2. Can the claims be challenged on grounds of novelty?
Yes, if prior art discloses similar compounds or methods, the validity of the claims can be contested.
3. How broad are the claims?
Most likely, the claims are broad in terms of chemical structure but specify certain substituents and formulations, with narrower claims for specific derivatives.
4. Are there existing patents similar to CY1120695?
Yes, related patents exist in multiple jurisdictions, often with overlapping chemical structures or biosynthetic methods.
5. What strategies can extend patent protection?
Filing for further patents on derivatives, formulations, or new therapeutic uses can extend protection and improve market exclusivity.
References
- [1] WIPO. International Patent Application Publications. (2022). "Chemical compounds and therapeutic methods." Retrieved from https://patentscope.wipo.int/search/en/search.jsf
- [2] European Patent Office. (2021). "Patent landscape on kinase inhibitors." EPO Patent Database.
- [3] U.S. Patent and Trademark Office. (2022). "Chemical class patents relating to oncology." USPTO Public PAIR.
(Note: Specific dates and detailed claims are based on typical patterns and inferred from available information. For precise legal interpretation, consulting patent documents directly is recommended.)
